Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced financial and operating results for the fourth quarter and full year ended December 31, 2012 and other business updates.
Total product revenue was $198.2 million for the fourth quarter of 2012, a 28% increase compared to $155.2 million for the fourth quarter of 2011. Total product revenue for the full year 2012 was $735.4 million, a 36% increase compared to $540.5 million for the full year 2011. XIFAXAN®revenue for the fourth quarter of 2012 was $147.0 million, a 37% increase compared to $107.2 million for the fourth quarter of 2011.
Total product revenue was $198.2 million for the fourth quarter of 2012, a 28% increase compared to $155.2 million for the fourth quarter of 2011. Total product revenue for the full year 2012 was $735.4 million, a 36% increase compared to $540.5 million for the full year 2011. XIFAXAN®revenue for the fourth quarter of 2012 was $147.0 million, a 37% increase compared to $107.2 million for the fourth quarter of 2011.
